承认和执行外国仲裁裁决公约

作者:法律资料网 时间:2024-05-21 04:11:43   浏览:9034   来源:法律资料网
下载地址: 点击此处下载

承认和执行外国仲裁裁决公约

联合国国际商事仲裁会议


承认和执行外国仲裁裁决公约

(1958年6月10日联合国国际商事仲裁会议通过)

第一条
(1)由于自然人或法人间的争执而引起的仲裁裁决,在一个国家的领土内作成,而在另一个国家请求承认和执行时,适用本公约。在一个国家请求承认和执行这个国家不认为是本国裁决的仲裁裁决时,也适用本公约。
(2)“仲裁裁决”不仅包括由为每一案件选定的仲裁员所作出的裁决,而且也包括由常设仲裁机构经当事人的提请而作出的裁决。
(3)任何缔约国在签署、批准或者加入本公约或者根据第10条通知扩延的时候,可以在互惠的基础上声明,本国只对另一缔约国领土内所作成的仲裁裁决的承认和执行,适用本公约。它也可以声明,本国只对根据本国法律属于商事的法律关系,不论是不是合同关系,所引起的争执适用本公约。
第二条
(1)如果双方当事人书面协议把由于同某个可以通过仲裁方式解决的事项有关的特定的法律关系,不论是不是合同关系,所已产生或可能产生的全部或任何争执提交仲裁,每一个缔约国应该承认这种协议。
(2)“书面协议”包括当事人所签署的或者来往书信、电报中所包含的合同中的仲裁条款和仲裁协议。
(3)如果缔约国的法院受理一个案件,而就这案件所涉及的事项,当事人已经达成本条意义内的协议时,除非该法院查明该项协议是无效的、未生效的或不可能实行的,应该依一方当事人的请求,令当事人把案件提交仲裁。
第三条 在以下各条所规定的条件下,每一个缔约国应该承认仲裁裁决有约束力,并且依照裁决需其承认或执行的地方程序规则予以执行。对承认或执行本公约所适用的仲裁裁决,不应该比对承认或执行本国的仲裁裁决规定实质上较烦的条件或较高的费用。
第四条
(1)为了获得前条所提到的承认和执行,申请承认和执行裁决的当事人应该在申请的时候提供:
(一)经正式认证的裁决正本或经正式证明的副本。
(二)第二条所提到的协议正本或经正式证明的副本。
(三)如果上述裁决或协议不是用裁决需其承认或执行的国家的正式语言作成,申请承认和执行裁决的当事人应该提出这些文件的此种译文。译文应该由一官方的或宣过誓的译员或一外交或领事代理人证明。
第五条
(1)被请求承认或执行裁决的管辖当局只有在作为裁决执行对象的当事人提出有关下列情况的证明的时候,才可以根据该当事人的要求,拒绝承认和执行该裁决:
(一)第二条所述的协议的双方当事人,根据对他们适用的法律,当时是处于某种无行为能力的情况之下;或者根据双方当事人选定适用的法律,或在没有这种选定的时候,根据作出裁决的国家的法律,下述协议是无效的;或者
(二)作为裁决执行对象的当事人,没有被给予指定仲裁员或者进行仲裁程序的适当通知,或者由于其他情况而不能对案件提出意见,或者
(三)裁决涉及仲裁协议所没有提到的,或者不包括裁仲协议规定之内的争执;或者裁决内含有对仲裁协议范围以外事项的决定;但是,对于仲裁协议范围以内的事项的决定,如果可以和对于仲裁协议范围以外的事项的决定分开,那么,这一部分的决定仍然可予以承认和执行;或者
(四)裁仲庭的组成或仲裁程序同当事人间的协议不符,或者当事人间没有这种协议时,同进行仲裁的国家的法律不符;或者
(五)裁决对当事人还没有约束力,或者裁决已经由作出裁决的国家或据其法律作出裁决的国家的管辖当局撤销或停止执行。
(2)被请求承认和执行仲裁裁决的国家的管辖当局如果查明有下列情况,也可以拒绝承认和执行:
(一)争执的事项,依照这个国家的法律,不可以用仲裁方式解决;或者
(二)承认或执行该项裁决将和这个国家的公共秩序相抵触。
第六条 如果已经向第五条(1)(五)所提到的管辖当局提出了撤销或停止执行仲裁裁决的申请,被请求承认或执行该项裁决的当局如果认为适当,可以延期作出关于执行裁决的决定,也可以依请求执行裁决的当事人的申请,命令对方当事人提供适当的担保。
第七条
(1)本公约的规定不影响缔约国参加的有关承认和执行仲裁裁决的多边或双边协定的效力,也不剥夺有关当事人在被请求承认或执行某一裁决的国家的法律或条约所许可的方式和范围内,可能具有的利用该仲裁裁决的任何权利。
(2)1923年关于仲裁条款的日内瓦议定书和1927年关于执行外国仲裁裁决的日内瓦公约,对本公约的缔约国,在它们开始受本公约约束的时候以及在它们受本公约约束的范围以内失效。
第八条
(1)本公约在1958年12月31日以前开放供联合国任何会员国,现在或今后是联合国专门机构成员的任何其它国家,现在或今后是国际法院规章缔约国的任何其他国家,或者经联合国大会邀请的任何其他国家的代表签署。
(2)本公约须经批准,批准书应当交存联合国秘书长。
第九条
(1)第八条所提到的一切国家都可以加入本公约。
(2)加入本公约应当将加入书交存联合国秘书长处。
第十条
(1)任何国家在签署、批准或加入本公约的时候,都可以声明:本公约将扩延到国际关系由该国负责一切或任何地区。这种声明在本公约对该国生效的时候生效。
(2)在签署、批准或加入本公约之后,要作这种扩延,应该通知联合国秘书长,并从联合国秘书长接到通知之后九十日起,或从本公约对该国生效之日起,取其在后者生效。
(3)关于在签署、批准或加入本公约的时候,本公约所没有扩延到的地区,各有关国家应当考虑采取必要步骤的可能性,以便使本公约的适用范围能够扩延到这些地区;但是,在有宪法上的必要时,须取得这些地区的政府的同意。
第十一条
(1)对于联邦制或者非单一制国家应当适用下列规定:
(一)关于属于联邦当局立法权限内的本公约条款,联邦政府的义务同非联邦制缔约国政府的义务一样。
(二)关于属于联邦成员或省立法权限内的本公约条款,如果联邦成员或省根据联邦宪法制度没有采取立法行动的义务,联邦政府应当尽早地把这些条款附以积极的建议以唤起联邦成员或省的相应机关的注意。
(三)本公约的联邦国家缔约国,根据任何其他缔约国通过联合国秘书长而提出的请求,应当提供关于该联邦及其构成单位有关本公约任何具体规定的法律和习惯,以表明已经在什么范围内采取立法或其他行动使该项规定生效。
第十二条
(1)本公约从第三个国家交存批准书或加入书之日后九十日起生效。
(2)在第三个国家交存批准书或加入书以后,本公约从每个国家交存批准书或加入书后九十日起对该国生效。
第十三条
(1)任何缔约国可以用书面通知联合国秘书长退出本公约。退约从秘书长接到通知之日后一年起生效。
(2)依照第十条规定提出声明或者通知的任何国家,随时都可以通知联合国秘书长,声明从秘书长接到通知之日后一年起,本公约停止扩延到有关地区。
(3)对于在退约生效以前已经进入承认或执行程序的仲裁裁决,本公约应继续适用。
第十四条
缔约国除了自己有义务适用本公约的情况外,无权利用本公约对抗其他缔约国。
第十五条
联合国秘书长应当将下列事项通知第八条中所提到的国家:
(一)依照第八条的规定签署和批准本公约;
(二)依照第九条的规定加入本公约;
(三)依照第一、十和十一条的规定的声明和通知;
(四)依照第十二条所规定的本公约的生效日期;
(五)依照第十三条所规定的退约和通知。
第十六条
(1)本公约的中、英、法、俄和西班牙各文本同等有效,由联合国档案处保存。
(2)联合国秘书长应当把经过证明的本公约副本送达第八条所提到的国家。

下载地址: 点击此处下载

关于印发蚌埠市政府投资的城市基础设施项目建设管理暂行规定的通知

安徽省蚌埠市人民政府


关于印发蚌埠市政府投资的城市基础设施项目建设管理暂行规定的通知

蚌政〔2010〕13号


各县、区人民政府,市政府各部门、各直属单位:

  经市政府同意,现将《蚌埠市政府投资的城市基础设施项目建设管理暂行规定》印发给你们,请抓紧贯彻执行。



   二○一○年二月九日


蚌埠市政府投资的城市基础设施项目建设管理暂行规定

  第一条 为规范政府投资的城市基础设施项目的建设和管理,根据《关于印发蚌埠市投融资及城市建设管理体制改革实施方案的通知》(蚌政〔2010〕12号),制定本规定。

  第二条 本规定适用于市本级财政性资金、中央和省补助资金(含国债资金),财政性资金作为还款来源或还款担保的借贷性资金,以及其他用于政府性投资项目的资金投资建设的城市基础设施项目,包括城市道路、公共交通、供水、排水、燃气、热力、园林、环卫、污水处理、垃圾处理、防洪、公路和地下公共设施等。

  第三条 城市基础设施项目实行项目储备制度。市住建、交通、水利、市容、规划等市直有关部门以及各区政府,根据全市国民经济和社会发展中长期规划、城市总体规划、土地利用规划、区域控制性规划、有关专项规划及实际发展需要,提出城市基础设施建设项目建议,报市发展和改革委员会。

  第四条 市发展和改革委员会会同市住建、规划、国土等部门,对有关市直部门、各区政府提出的项目建议进行初步审查,提出初审意见后,由市投融资管理委员会办公室上报市投融资管理委员会审定,纳入政府投资项目储备库。

  第五条 市投融资管理中心、市发展和改革委员会于每年第三季度组织市住建、规划、重点工程建设管理等部门,对列入储备库的项目进行筛选,提出下一年度建设项目投融资计划,经市投融资管理委员会审定后,分别由市发展和改革委员会下达年度项目建设投资计划、市投融资管理中心下达项目建设融资计划。

  第六条 列入年度建设计划的项目等同于立项,市项目行业主管部门牵头组织编制项目可行性研究报告,并以市城投公司名义报送市发展和改革委员会审批。符合规定条件的,市发展和改革委员会及时批准,向市城投公司下达可研批复,并抄送市项目行业主管部门、市投融资管理中心和市重点工程建设管理局等相关部门。

  第七条 市重点工程建设管理局依据批准的项目可行性研究报告,会同行业主管部门或使用单位编制初步设计(含概算),并组织相关单位进行勘察及施工图设计、审图和预算编制。

  第八条 市重点工程建设管理局依据批准的初步设计和施工图设计文件,组织项目实施,并严格按照批准的建设规模、建设内容、建设标准实行合同管理,对项目建设实施全过程管理。

  市重点工程建设管理局应当按照有关法律、法规规定和基本建设程序要求,办理项目建设相关行政许可手续。

  市重点工程建设管理局应当将合同文本等资料及时报送市项目行业主管部门、市投融资管理中心和市城投公司备案。

  第九条 市重点工程建设管理局具体负责项目的施工、监理等招投标工作,市城投公司及相关项目行业主管部门参与资格预审和制定招标文件等工作,市相关项目行业主管部门负责行业监管。

  第十条 项目建设过程中,因设计变更可能超过概算的,市重点工程建设管理局应报项目行业主管部门初审后,由市发展和改革委员会会同有关部门审核确定,并按规定办理有关批准手续。

  第十一条 项目建设涉及征地拆迁的,由项目所在区政府负责征地拆迁,按照市政府确定的征地拆迁方案,按时完成征地拆迁工作。征地拆迁费用应分项目列入工程概算和决算。

  第十二条 市重点工程建设管理局应当根据项目建设投资额、施工合同和工程计划进度,按季编制分月资金使用计划,报市投融资管理中心和市城投公司确定贷款提款、资金拨付计划。

  第十三条 项目建设资金由市重点工程建设管理局根据施工合同和工程实际进度提出支付意见,市城投公司应当及时审核拨付资金。资金支付一般实行直接支付。

  征地拆迁费用由市重点工程建设管理局牵头组织有关部门审核确定后,市城投公司应及时将资金支付给有关区政府或其他收款人。

  第十四条 工程竣工后,市项目审批部门、市直各有关行业主管部门组织验收。市重点工程建设管理局应当在工程验收合格后3个月内将工程完成情况(包括竣工决算)汇总报送市城投公司,经财政、审计部门核查审计后,办理竣工决算批复和资产移交手续。

  第十五条 市各有关部门应当加强协调、相互配合,确保项目建设顺利进行。

  市发展改革、财政、投融资管理、规划、国土、审计、监察等部门应当认真履行职责,依法对项目建设加强监督管理,做好项目协调和服务工作。

  第十六条 本规定所指的市项目行业主管部门,系城市基础设施项目涉及的市住建、交通、水利、市容等市直主管部门。其中住建、市容部门以外的城市基础设施项目,项目实施主体为交通、水利、蚌投集团等提出项目的责任单位,各区、开发区提出的项目,可按本规定通过市城投公司平台进行融资,项目实施主体为各区、开发区。

  第十七条 政府投资的社会公益性项目,参照本规定执行。

  第十八条 本规定自发布之日起施行。


Provisions for Supervision of Drug Distribution

Commissioner of SFDA


Provisions for Supervision of Drug Distribution



(SFDA Decree No.26)

The Provisions for Supervision of Drug Distribution, adopted at the executive meeting of the State Food and Drug Administration on December 8, 2006, is hereby promulgated and shall go into effect as of May 1, 2007.


Shao Mingli
Commissioner of SFDA
January 31, 2007





Provisions for Supervision of Drug Distribution


Chapter I

Article 1 These Provisions are formulated for the purposes of strengthening drug supervision, regulating drug distribution order and ensuring drug quality in accordance with the Drug Administration Law of the People’s Republic of China (hereinafter referred to as Drug Administration Law), the Regulations for Implementation of the Drug Administration Law of the People’s Republic of China (hereinafter referred to as Regulations for Implementation of the Drug Administration Law) and the requirements of the relevant law and regulations.

Article 2 Any institutions or individuals engaged in the purchase, sales and supervision of drugs in the People’s Republic of China shall abide by the Provisions.

Article 3 Drug manufacturers, distributors and medical institutions shall be responsible for the quality of the drugs that they produce, distribute or use.

Drug manufacturers and distributors shall carry out reforms and innovations in the direction of pharmaceutical logistics provided that drug quality is assured.

Article 4 The drug regulatory departments encourage individuals and organizations to involve in the social supervision on drug distribution. Individuals or organizations have the right to report or accuse of any violation of the Provisions to the drug regulatory departments.


Chapter II Supervision on Drug Purchase and Sales by Manufacturers and Distributors

Article 5 Drug manufacturers or distributors shall be responsible for their drug purchases and sales, and liable for the purchases and sales activities of their sales staff or offices in the name of their enterprise.

Article 6 Drug manufacturers or distributors shall train their purchase and sales staff on drug related laws, regulations and professional knowledge, and establish training records including time, venue, content and trainees.

Article 7 Drug manufacturers or distributors shall strengthen the management of the sales staff and set up specific rules for their sales behaviors.

Article 8 Drug manufacturers or distributors shall not store or spot trade drugs on the premises not approved by the drug regulatory departments.

Article 9 Drug manufacturers shall sell drugs that they produce in the name of themselves, and shall not sell any drug that they produce for contract manufacturing or any drugs produced by others.

Article 10 Where a drug manufacturer or wholesaler sells drugs, it shall provide the following materials:
(1) Copies of the Drug Manufacturing Certificate or Drug Supply Certificate, stamped with the seal of the enterprise, and the business license;
(2) Copies of the approval documents for the drug to be sold, stamped with the seal of the enterprise ;
(3) For import drug sales, relevant proof documents should be provided in accordance with the related provisions of the State.

Where a drug manufacturer or wholesaler sends any of its sales staff to sell drugs, it shall, in addition to the materials prescribed in the previous paragraph of this Article, provide a copy of the authorization letter with the seal of the enterprise. The original authorization letter shall contain the authorized drugs, regions and time of validity for drug sales, indicate the identity card numbers of the sales staff, and be stamped with the enterprise seal and legal representative seal (or signature). The sales staff shall show the original authorization letter and identity card for the check by drug purchasers.

Article 11 Where a drug manufacturer or wholesaler sells drugs, it shall provide sales document indicating supplier’s name, drug name, manufacturer, batch number, quantity, price, etc.

Where a drug retailer sells drugs, it shall provide sales document indicating drug name, manufacturer, quantity, price, batch number, etc.

Article 12 Where a drug manufacturer or distributor purchases drugs, it shall request, examine and retain the relevant certificates and documents of the supplier in accordance with the requirements set forth in Article 10 of the Provisions, and request and retain sales document in accordance with the requirements set forth in Article 11 of the Provisions.

The documents retained by the drug manufacturer or distributor in accordance with the previous paragraph of this Article shall be kept till one year after the date of expiry, but not less than three years.

Article 13 Where a drug manufacturer or distributor knows or should know that any person without certificates produces or distributes drugs, it shall not provide the person with any drug.

Article 14 A drug manufacturer or distributor shall not provide premises, qualifications documents, notes, etc. as conveniences for others to distribute drugs in its own name.

Article 15 A drug manufacturer or distributor shall not spot trade drugs by means of exhibition, exposition, trade fair, commodity fair or product promotion event.

Article 16 A drug distributor shall not purchase or sell pharmaceutical preparations prepared by medical institutions.

Article 17 A drug distributor shall not change its distribution mode without approval of the drug regulatory department.

A drug distributor shall operate within the approved distribution scope in the Drug Supply Certificate.

Article 18 A drug retailer shall, pursuant to the requirements of drug classification regulations set forth by the State Food and Drug Administration, sell prescription drugs in the presence of prescriptions.

Any drug retailer selling prescription drugs or Class A non-prescription drugs shall, in the absence of its licensed pharmacists and other qualified pharmaceutical professionals, put up a public notice and stop selling prescription drugs and Class A non-prescription drugs.

Article 19 For drugs that need low-temperature or cold storage as specified in drug insert sheets, the drug manufacturer or distributor shall transport and store the drugs with low-temperature or cold storage facilities in accordance with the relevant provisions.

When finding any drug manufacturer or distributor violates the requirements in the previous paragraph of this article, the drug regulatory department shall seal up or seize the drugs concerned immediately and deal with the matter in accordance with law.

Article 20 A drug manufacturer or distributor shall not provide the public with prescription drug or Class A non-prescription drug by means of tie-in sale, offering free drugs in association with sales of drug or commodity sale, etc.

Article 21 A drug manufacturer or distributor shall not sell prescription drugs directly to the public by post or over internet.

Article 22 Any illegal purchase of drugs is prohibited.


Chapter III Supervision on Drug Purchase and Storage by Medical Institutions

Article 23 The pharmacy established by a medical institution shall have the premise, equipment, storage facilities, hygienic environment, and pharmaceutical professionals required for drug dispensing. It shall also have the drug quality control units or personnel, and establish a system for drug storage.

Article 24 Where a medical insititution purchases drugs, it shall request, examine and retain the relevant certificates, documents and notes of the supplier in accordance with the requirements set forth in Article 12 of the Provisions.

Article 25 Where a medical institution purchases drugs, it shall establish and apply an examination and acceptance system, and keep authentic and complete purchase records. Purchase records shall indicate the adopted name of the drug in China, manufacturer (for Chinese crude drug, the origin should be noted), dosage form, date of expiry, drug approval number, supplier, quantity, price and date of purchase.

Drug purchase records shall be kept till one year after the date of expiry, but not less than three years.

Article 26 A medical institution shall establish and apply a system for drug storage and maintenance, and take necessary measures to ensure drug quality, such as cold storage, protection against freeze and humidity, ventilation, moisture proof, protection from direct light and fire, and avoidance of insects and rodents.

A medical institution shall store drugs and non-drug products separately; Chinese crude drugs, prepared slices of Chinese crude drugs, pharmaceuticals, and traditional Chinese medicine preparations shall be stored separately by category.

Article 27 A medical institution or family planning technical service institution shall not directly provide drugs for patients without diagnosis or treatment.

Article 28 A medical institution shall not sell prescription drugs directly to the public by post or over internet.

Article 29 Where a medical institution purchases drugs via a centralized tendering, it shall comply with the relevant requirements of the Drug Administration Law, Regulations for Implementation of the Drug Administration Law and the Provisions.


Chapter IV Legal Liabilities

Article 30 In any of the following circumstances, the drug manufacturer or distributor shall be instructed to rectify within a time limit and given a disciplinary warning; and if the drug manufacturer or distributor fails to do so, it shall be fined not less than RMB 5,000 yuan but not more than RMB 20,000 yuan:
(1) any drug manufacturer or distributor in violation of Article 6 of the Provisions;
(2) any drug manufacturer or wholesaler in violation of the first paragraph of Article 11 of the Provisions;
(3) any drug manufacturer or distributor, in violation of Article 12 of the Provisions, failing to keep the relevant documents as required.

Article 31 Any drug manufacturer or distributor in violation of Article 7 of the Provisions shall be given a disciplinary warning and instructed to rectify within a time limit.

Article 32 In accordance with the provisions in Article 73 of the Drug Administration Law, in any of the following circumstances, the drugs illegally sold and the illegal gains therefrom shall be confiscated, and the drug manufacturer or distributor shall be fined not less than two times but not more than five times the value of the drugs illegally sold:
(1) any drug manufacturer or distributor, in violation of Article 8 of the Provisions, spot trading drugs on the premises not approved by the drug regulatory departments.
(2) any drug manufacturer in violation of Article 9 of the Provisions;
(3) any drug manufacturer or distributor in violation of Article 15 of the Provisions;
(4) any drug distributor in violation of Article 17 of the Provisions.

Article 33 Any drug manufacturer or distributor, in violation of Article 8 of the Provisions, storing drugs on the premises not approved by the drug regulatory departments,shall be punished pursuant to the provisions in Article 74 of the Regulations for Implementation of the Drug Administration Law.

Article 34 Any drug retailer in violation of the provisions in the second paragraph of Article 11 of the Provisions shall be instructed to rectify and given a disciplinary warning; and if the drug retailer fails to do so within a time limit, it shall be fined not more than RMB 500 yuan.

Article 35 Where a drug manufacturer or distributor, in violation of Article 13 of the Provisions, knows or should know that any person without certificates produces or distributes drugs, but still provide the person with drugs, they shall be given a disciplinary warning, instructed to rectify and fined not more than RMB 10,000 yuan. If the circumstances are serious, they shall be fined not less than RMB 10,000 yuan but not more than RMB 30,000 yuan.

Article 36 Drug manufacturers and distributors in violation of Article 14 of the Provisions shall be punished pursuant to the provisions in Article 82 of the Drug Administration Law.

Article 37 Where a drug distributor, in violation of Article 16 of the Provisions, purchases or sells pharmaceutical preparations dispensed by medical institutions, it shall be punished pursuant to the provisions in Article 80 of the Drug Administration Law.

Article 38 Any drug retailer in violation of the first paragraph of Article 18 of the Provisions shall be instructed to rectify within a time limit and given a disciplinary warning; if it fails to do so or the circumstances are serious, it shall be fined not more than RMB 1,000 yuan.

Where a drug retailer, in violation of the second paragraph of Article 18 of the Provisions, sells prescription drugs or Class A non-prescription drugs in absence of licensed pharmacists or other qualified pharmaceutical professionals, it shall be instructed to rectify within a time limit and given a disciplinary warning; if it fails to do so, it shall be fined not more than RMB 1,000 yuan.

Article 39 Where a drug manufacturer or wholesaler, in violation of Article 19 of the Provisions, fails to transport drugs under low-temperature or cold storage conditions as specified in insert sheets, it shall be given a disciplinary warning and instructed to rectify within a time limit; if it fails to do as instructed, it shall be fined not less than RMB 5,000 yuan but not more than RMB 20,000 yuan. Where the drugs concerned are legally proved to be counterfeit or substandard drugs, the drug manufacturer or wholesaler shall be punished in accordance with the relevant provisions of the Drug Administration Law.

Where a drug manufacturer or wholesaler, in violation of Article 19 of the Provisions, fails to store drugs under low-temperature or cold storage conditions as specified in insert sheets, it shall be punished pursuant to the provisions in Article 79 of the Drug Administration Law. Where the drugs concerned are legally proved to be counterfeit or substandard drugs, the drug manufacturer or wholesaler shall be punished in accordance with the relevant provisions of the Drug Administration Law.

Article 40 Any drug manufacturer or distributor in violation of Article 20 of the Provisions shall be instructed to rectify within a time limit and given a disciplinary warning; if the drug manufacturer or distributor fails to do so or the circumstances are serious, they shall be fined not more than two times the value of the free drugs offered, but not more than RMB 30,000 yuan.

Article 41 Any institution, in violation of Article 23 to Article 27 of the Provisions, shall be instructed to rectify within a time limit; if the circumstances are serious, it shall be announced.

Article 42 Where a drug manufacturer or distributor in violation of Article 21 of the Provisions or a medical institution in violation of Article 28 of the Provisions sells prescription drugs directly to the public by post, over internet, etc., they shall be instructed to rectify, given a disciplinary warning, and fined not more than two times the value of the drugs sold, but not more than RMB 30,000 yuan.

Article 43 Any illegal purchase of drugs, in violation of Article 22 of the Provisions, shall be punished pursuant to the provisions in Article 73 of the Drug Administration Law.

Article 44 Where a drug regulatory department or its staff that neglects its duty fails to stop or punish illegal activities that should be stopped or punished, administrative sanctions shall be imposed to the person directly in charge and other persons directly responsible. If a crime is constituted, criminal liabilities shall be investigated in accordance with law.


Chapter V Supplementary Provisions

Article 45 Spot trading of drugs in the Provisions refers to the activity that drug manufacturers, distributors or their appointed sales staff carry and sell drugs to unspecified objects on spot other than the premises approved by the drug regulatory departments.

Article 46 With respect to the supervision on the distribution of specially controlled drugs, vaccines, and military medicines, if otherwise provided by the relevant laws, regulations and provisions, they shall prevail.

Article 47 The Provisions shall come into force as of May 1, 2007. As of the date when the Provisions goes into effect, the Provisions for Supervision of Drug Distribution (Interim) (SFDA Decree No.7) implemented on August 1, 1999 shall be annulled therefrom.